Nuria Lara-Castillo1, Mark L Johnson2. 1. Department of Oral and Craniofacial Sciences, UMKC School of Dentistry, 650 East 25th Street, Kansas City, MO, 64108, USA. 2. Department of Oral and Craniofacial Sciences, UMKC School of Dentistry, 650 East 25th Street, Kansas City, MO, 64108, USA. johnsonmark@umkc.edu.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to describe the current state of our thinking regarding bone-muscle interactions beyond the mechanical perspective. RECENT FINDINGS: Recent and prior evidence has begun to dissect many of the molecular mechanisms that bone and muscle use to communicate with each other and to modify each other's function. Several signaling factors produced by muscle and bone have emerged as potential mediators of these biochemical/molecular interactions. These include muscle factors such as myostatin, Irisin, BAIBA, IL-6, and the IGF family and the bone factors FGF-23, Wnt1 and Wnt3a, PGE2, FGF9, RANKL, osteocalcin, and sclerostin. The identification of these signaling molecules and their underlying mechanisms offers the very real and exciting possibility that new pharmaceutical approaches can be developed that will permit the simultaneous treatments of diseases that often occur in combination, such as osteoporosis and sarcopenia.
PURPOSE OF REVIEW: The purpose of this review is to describe the current state of our thinking regarding bone-muscle interactions beyond the mechanical perspective. RECENT FINDINGS: Recent and prior evidence has begun to dissect many of the molecular mechanisms that bone and muscle use to communicate with each other and to modify each other's function. Several signaling factors produced by muscle and bone have emerged as potential mediators of these biochemical/molecular interactions. These include muscle factors such as myostatin, Irisin, BAIBA, IL-6, and the IGF family and the bone factors FGF-23, Wnt1 and Wnt3a, PGE2, FGF9, RANKL, osteocalcin, and sclerostin. The identification of these signaling molecules and their underlying mechanisms offers the very real and exciting possibility that new pharmaceutical approaches can be developed that will permit the simultaneous treatments of diseases that often occur in combination, such as osteoporosis and sarcopenia.
Authors: S L Nehlsen-Cannarella; O R Fagoaga; D C Nieman; D A Henson; D E Butterworth; R L Schmitt; E M Bailey; B J Warren; A Utter; J M Davis Journal: J Appl Physiol (1985) Date: 1997-05
Authors: L Grobet; L J Martin; D Poncelet; D Pirottin; B Brouwers; J Riquet; A Schoeberlein; S Dunner; F Ménissier; J Massabanda; R Fries; R Hanset; M Georges Journal: Nat Genet Date: 1997-09 Impact factor: 38.330
Authors: Walter Sepúlveda-Loyola; Steven Phu; Ebrahim Bani Hassan; Sharon L Brennan-Olsen; Jesse Zanker; Sara Vogrin; Romy Conzade; Ben Kirk; Ahmed Al Saedi; Vanessa Probst; Gustavo Duque Journal: J Am Med Dir Assoc Date: 2019-10-25 Impact factor: 4.669